Glycine transporter inhibitors

A new avenue for managing neuropathic pain

M. Al-Khrasani, Amir Mohammadzadeh, Mihály Balogh, Kornél Király, Szilvia Barsi, Benjamin Hajnal, L. Köles, Z. Zádori, L. Hársing

Research output: Review article

Abstract

Interneurons operating with glycine neurotransmitter are involved in the regulation of pain transmission in the dorsal horn of the spinal cord. In addition to interneurons, glycine release also occurs from glial cells neighboring glutamatergic synapses in the spinal cord. Neuronal and glial release of glycine is controlled by glycine transporters (GlyTs). Inhibitors of the two isoforms of GlyTs, the astrocytic type-1 (GlyT-1) and the neuronal type-2 (GlyT-2), decrease pain sensation evoked by injuries of peripheral sensory neurons or inflammation. The function of dorsal horn glycinergic interneurons has been suggested to be reduced in neuropathic pain, which can be reversed by GlyT-2 inhibitors (Org-25543, ALX1393). Several lines of evidence also support that peripheral nerve damage or inflammation may shift glutamatergic neurochemical transmission from N-methyl-D aspartate (NMDA) NR1/NR2A receptor- to NR1/NR2B receptor-mediated events (subunit switch). This pathological overactivation of NR1/NR2B receptors can be reduced by GlyT-1 inhibitors (NFPS, Org-25935), which decrease excessive glycine release from astroglial cells or by selective antagonists of NR2B subunits (ifenprodil, Ro 25-6981). Although several experiments suggest that GlyT inhibitors may represent a novel strategy in the control of neuropathic pain, proving this concept in human beings is hampered by lack of clinically applicable GlyT inhibitors. We also suggest that drugs inhibiting both GlyT-1 and GlyT-2 non-selectively and reversibly, may favorably target neuropathic pain. In this paper we overview inhibitors of the two isoforms of GlyTs as well as the effects of these drugs in experimental models of neuropathic pain. In addition, the possible mechanisms of action of the GlyT inhibitors, i.e. how they affect the neurochemical and pain transmission in the spinal cord, are also discussed. The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions.

Original languageEnglish
Pages (from-to)143-158
Number of pages16
JournalBrain Research Bulletin
Volume152
DOIs
Publication statusPublished - okt. 1 2019

Fingerprint

Glycine Plasma Membrane Transport Proteins
Neuralgia
Glycine
Interneurons
Pain
Neuroglia
Spinal Cord
Protein Isoforms
Inflammation
Sensory Receptor Cells
N-Methylaspartate
Peripheral Nerves
Pharmaceutical Preparations
Synapses
Neurotransmitter Agents
Theoretical Models
Wounds and Injuries

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Glycine transporter inhibitors : A new avenue for managing neuropathic pain. / Al-Khrasani, M.; Mohammadzadeh, Amir; Balogh, Mihály; Király, Kornél; Barsi, Szilvia; Hajnal, Benjamin; Köles, L.; Zádori, Z.; Hársing, L.

In: Brain Research Bulletin, Vol. 152, 01.10.2019, p. 143-158.

Research output: Review article

Al-Khrasani, M. ; Mohammadzadeh, Amir ; Balogh, Mihály ; Király, Kornél ; Barsi, Szilvia ; Hajnal, Benjamin ; Köles, L. ; Zádori, Z. ; Hársing, L. / Glycine transporter inhibitors : A new avenue for managing neuropathic pain. In: Brain Research Bulletin. 2019 ; Vol. 152. pp. 143-158.
@article{3f76f2c7bf0d49d48d29d8411bbb0aa1,
title = "Glycine transporter inhibitors: A new avenue for managing neuropathic pain",
abstract = "Interneurons operating with glycine neurotransmitter are involved in the regulation of pain transmission in the dorsal horn of the spinal cord. In addition to interneurons, glycine release also occurs from glial cells neighboring glutamatergic synapses in the spinal cord. Neuronal and glial release of glycine is controlled by glycine transporters (GlyTs). Inhibitors of the two isoforms of GlyTs, the astrocytic type-1 (GlyT-1) and the neuronal type-2 (GlyT-2), decrease pain sensation evoked by injuries of peripheral sensory neurons or inflammation. The function of dorsal horn glycinergic interneurons has been suggested to be reduced in neuropathic pain, which can be reversed by GlyT-2 inhibitors (Org-25543, ALX1393). Several lines of evidence also support that peripheral nerve damage or inflammation may shift glutamatergic neurochemical transmission from N-methyl-D aspartate (NMDA) NR1/NR2A receptor- to NR1/NR2B receptor-mediated events (subunit switch). This pathological overactivation of NR1/NR2B receptors can be reduced by GlyT-1 inhibitors (NFPS, Org-25935), which decrease excessive glycine release from astroglial cells or by selective antagonists of NR2B subunits (ifenprodil, Ro 25-6981). Although several experiments suggest that GlyT inhibitors may represent a novel strategy in the control of neuropathic pain, proving this concept in human beings is hampered by lack of clinically applicable GlyT inhibitors. We also suggest that drugs inhibiting both GlyT-1 and GlyT-2 non-selectively and reversibly, may favorably target neuropathic pain. In this paper we overview inhibitors of the two isoforms of GlyTs as well as the effects of these drugs in experimental models of neuropathic pain. In addition, the possible mechanisms of action of the GlyT inhibitors, i.e. how they affect the neurochemical and pain transmission in the spinal cord, are also discussed. The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions.",
keywords = "Glycine transporter inhibitors, Glycine transporters, Neuropathic pain, NMDA receptors, Spinal cord",
author = "M. Al-Khrasani and Amir Mohammadzadeh and Mih{\'a}ly Balogh and Korn{\'e}l Kir{\'a}ly and Szilvia Barsi and Benjamin Hajnal and L. K{\"o}les and Z. Z{\'a}dori and L. H{\'a}rsing",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.brainresbull.2019.07.008",
language = "English",
volume = "152",
pages = "143--158",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Glycine transporter inhibitors

T2 - A new avenue for managing neuropathic pain

AU - Al-Khrasani, M.

AU - Mohammadzadeh, Amir

AU - Balogh, Mihály

AU - Király, Kornél

AU - Barsi, Szilvia

AU - Hajnal, Benjamin

AU - Köles, L.

AU - Zádori, Z.

AU - Hársing, L.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Interneurons operating with glycine neurotransmitter are involved in the regulation of pain transmission in the dorsal horn of the spinal cord. In addition to interneurons, glycine release also occurs from glial cells neighboring glutamatergic synapses in the spinal cord. Neuronal and glial release of glycine is controlled by glycine transporters (GlyTs). Inhibitors of the two isoforms of GlyTs, the astrocytic type-1 (GlyT-1) and the neuronal type-2 (GlyT-2), decrease pain sensation evoked by injuries of peripheral sensory neurons or inflammation. The function of dorsal horn glycinergic interneurons has been suggested to be reduced in neuropathic pain, which can be reversed by GlyT-2 inhibitors (Org-25543, ALX1393). Several lines of evidence also support that peripheral nerve damage or inflammation may shift glutamatergic neurochemical transmission from N-methyl-D aspartate (NMDA) NR1/NR2A receptor- to NR1/NR2B receptor-mediated events (subunit switch). This pathological overactivation of NR1/NR2B receptors can be reduced by GlyT-1 inhibitors (NFPS, Org-25935), which decrease excessive glycine release from astroglial cells or by selective antagonists of NR2B subunits (ifenprodil, Ro 25-6981). Although several experiments suggest that GlyT inhibitors may represent a novel strategy in the control of neuropathic pain, proving this concept in human beings is hampered by lack of clinically applicable GlyT inhibitors. We also suggest that drugs inhibiting both GlyT-1 and GlyT-2 non-selectively and reversibly, may favorably target neuropathic pain. In this paper we overview inhibitors of the two isoforms of GlyTs as well as the effects of these drugs in experimental models of neuropathic pain. In addition, the possible mechanisms of action of the GlyT inhibitors, i.e. how they affect the neurochemical and pain transmission in the spinal cord, are also discussed. The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions.

AB - Interneurons operating with glycine neurotransmitter are involved in the regulation of pain transmission in the dorsal horn of the spinal cord. In addition to interneurons, glycine release also occurs from glial cells neighboring glutamatergic synapses in the spinal cord. Neuronal and glial release of glycine is controlled by glycine transporters (GlyTs). Inhibitors of the two isoforms of GlyTs, the astrocytic type-1 (GlyT-1) and the neuronal type-2 (GlyT-2), decrease pain sensation evoked by injuries of peripheral sensory neurons or inflammation. The function of dorsal horn glycinergic interneurons has been suggested to be reduced in neuropathic pain, which can be reversed by GlyT-2 inhibitors (Org-25543, ALX1393). Several lines of evidence also support that peripheral nerve damage or inflammation may shift glutamatergic neurochemical transmission from N-methyl-D aspartate (NMDA) NR1/NR2A receptor- to NR1/NR2B receptor-mediated events (subunit switch). This pathological overactivation of NR1/NR2B receptors can be reduced by GlyT-1 inhibitors (NFPS, Org-25935), which decrease excessive glycine release from astroglial cells or by selective antagonists of NR2B subunits (ifenprodil, Ro 25-6981). Although several experiments suggest that GlyT inhibitors may represent a novel strategy in the control of neuropathic pain, proving this concept in human beings is hampered by lack of clinically applicable GlyT inhibitors. We also suggest that drugs inhibiting both GlyT-1 and GlyT-2 non-selectively and reversibly, may favorably target neuropathic pain. In this paper we overview inhibitors of the two isoforms of GlyTs as well as the effects of these drugs in experimental models of neuropathic pain. In addition, the possible mechanisms of action of the GlyT inhibitors, i.e. how they affect the neurochemical and pain transmission in the spinal cord, are also discussed. The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions.

KW - Glycine transporter inhibitors

KW - Glycine transporters

KW - Neuropathic pain

KW - NMDA receptors

KW - Spinal cord

UR - http://www.scopus.com/inward/record.url?scp=85069661122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069661122&partnerID=8YFLogxK

U2 - 10.1016/j.brainresbull.2019.07.008

DO - 10.1016/j.brainresbull.2019.07.008

M3 - Review article

VL - 152

SP - 143

EP - 158

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

ER -